Aricept Evess Dosage/Direction for Use

Mild to Moderate Alzheimer's Disease: The dosages shown to be effective in controlled clinical trials are 5 and 10 mg administered once daily.
The higher dose of 10 mg did not provide a statistically significant greater clinical benefit than 5 mg. There is a suggestion, however, based upon order of group mean scores and dose trend analyses of data from these clinical trials, that a daily dose of Aricept Evess 10 mg might provide additional benefit for some patients. Accordingly, whether or not employ a dose of 10 mg is a matter of prescriber and patient preference.
Severe Alzheimer's Disease: Aricept Evess has been shown to be effective in controlled clinical trials at a dose of 10 mg administered once daily.
Evidence from the controlled trials in mild to moderate Alzheimer's disease indicates that the 10-mg dose, with a 1-week titration, is likely to be associated with a higher incidence of cholinergic adverse events than the 5-mg dose. In open-label trials using a 6-week titration, the frequency of these same adverse events was similar between the 5- and 10-mg dose groups. Therefore, because steady state is not achieved for 15 days and the incidence of untoward effects may be influenced by the rate of dose escalation, a dose of 10 mg should not be achieved until patients have been on a daily dose of 5 mg for 4-6 weeks.
Renal and Hepatic Impairment: A similar dose schedule can be followed for patients with renal impairment, as clearance of donepezil HCl is not affected by this condition.
Due to possible increased exposure in mild to moderate hepatic impairment (see Pharmacokinetics under Actions), dose escalation should be performed according to individual tolerability. There are no data for patients with severe hepatic impairment.
Administration: Aricept Evess should be taken in the evening, just prior to retiring. It can be taken with/without food.
Allow Aricept Evess to dissolve on the tongue and follow with water.